



MEDICAL TIPS

DIABIZ Tablets

Issue IV, No.13, 2023

Dapagliflozin efficacy as an add-on therapy in double and triple-drug regimens: A meta-analysis of randomized control trial

Saikia D et al. Journal of Drug Delivery and Therapeutics 2023; 31(1): 76-83.

- SGLT2 inhibitors like dapagliflozin are a new class of drugs that are used as an add-on therapy to treat type 2 diabetes.
- A systemic review and meta-analysis was performed on randomized clinical trial data to evaluate the efficacy of various combinations of dapagliflozin with other OHAs.
- Data from 12 RCTs including 8000 participants were divided into three groups of SAXA+DAPA+MET, SAXA+MET and DAPA+MET and the parameters were analyzed.
- Changes in parameters like HbA1c, fasting blood glucose, body weight and systolic and diastolic blood pressure were analysed.

Dapagliflozin, when given in combination, showed a major improvement in HbA1c and FBG levels but did not affect body weight. It was shown to be more effective when given in triple combination therapy.

